Published in Blood Weekly, May 2nd, 2002
The single-blind, dose-comparison study will evaluate the safety and tolerability of a short course of HEMOLINK in 50 patients with lung or ovarian cancer who are being treated with erythropoietin for chemotherapy-induced anemia. The multicenter study will be led by investigators at Duke University and is expected to begin enrolling patients in June of 2002.
"The market opportunity created by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.